Literature DB >> 20818449

Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT--results of a multicentre study.

L Vagliano1, C Feraut, G Gobetto, A Trunfio, A Errico, V Campani, G Costazza, A Mega, V Matozzo, M Berni, F Alberani, M M Banfi, L Martinelli, S Munaron, L Orlando, L Lubiato, S Leanza, R Guerrato, A Rossetti, M Messina, L Barzetti, G Satta, V Dimonte.   

Abstract

Oral mucositis (OM) is a common side effect experienced during haematopoietic SCT (HSCT), and it can have a significant impact on the quality of life of patients. A descriptive nurse-led study was undertaken in 19-member centres of the Italian national transplant group (GITMO) evaluating incidence, severity and duration of OM in patients undergoing HSCT. Data from 1841 patients between 2002 and 2006 was analyzed. Initial medical history and oral cavity assessment was performed. Assessment was repeated on the day of transplant, then daily, using the WHO (World Health Organisation) oral toxicity scale. A total of 71% of the patients evaluated developed mucositis and 21.6% developed severe mucositis. Duration of OM in most cases lasted for 10-14 days and resolved along with marrow reconstitution. Oral mucostitis is a frequent side effect in patients undergoing HSCT. The onset of severe mucositis seems to be related to the conditioning regimen used. This database provides a descriptive overview of the incidence and severity of mucositis and has encouraged participating centres to adopt routine evaluation and measurement of the oral cavity. The assessment tools are still used in some centres, providing a basis for further collaborative research projects.

Entities:  

Mesh:

Year:  2010        PMID: 20818449     DOI: 10.1038/bmt.2010.184

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  28 in total

1.  A comparison of oral mucositis in allogeneic hematopoietic stem cell transplantation between conventional and reduced-intensity regimens.

Authors:  Haruhiko Kashiwazaki; Takae Matsushita; Junichi Sugita; Akio Shigematsu; Kumiko Kasashi; Yutaka Yamazaki; Takashi Kanehira; Takeshi Kondo; Tomoyuki Endo; Junji Tanaka; Satoshi Hashino; Mitsufumi Nishio; Masahiro Imamura; Yoshimasa Kitagawa; Nobuo Inoue
Journal:  Support Care Cancer       Date:  2011-04-15       Impact factor: 3.603

2.  New photobiomodulation protocol prevents oral mucositis in hematopoietic stem cell transplantation recipients-a retrospective study.

Authors:  Camila Weissheimer; Marina Curra; Lauro J Gregianin; Liane E Daudt; Vivian P Wagner; Marco Antonio T Martins; Manoela D Martins
Journal:  Lasers Med Sci       Date:  2017-08-24       Impact factor: 3.161

3.  Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.

Authors:  Ajay K Nooka; Heather R Johnson; Jonathan L Kaufman; Christopher R Flowers; Amelia Langston; Conor Steuer; Michael Graiser; Zahir Ali; Nishi N Shah; Sravanti Rangaraju; Dana Nickleach; Jingjing Gao; Sagar Lonial; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-06       Impact factor: 5.742

4.  A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy.

Authors:  Rajesh V Lalla; Gary B Gordon; Mark Schubert; Sol Silverman; Mark Hutten; Stephen T Sonis; Francis LeVeque; Douglas E Peterson
Journal:  Support Care Cancer       Date:  2011-10-01       Impact factor: 3.603

5.  The relationship between oral mucositis and levels of pro-inflammatory cytokines in serum and in gingival crevicular fluid in allogeneic stem cell recipients.

Authors:  Karin Garming Legert; Georgios Tsilingaridis; Mats Remberger; Olle Ringdèn; Anders Heimdahl; Tülay Yucel-Lindberg; Göran Dahllöf
Journal:  Support Care Cancer       Date:  2014-11-30       Impact factor: 3.603

6.  Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.

Authors:  Chunyan Gao; Jocelyn A Schroeder; Feng Xue; Weiqing Jing; Yuanhua Cai; Amelia Scheck; Saravanan Subramaniam; Sridhar Rao; Hartmut Weiler; Agnieszka Czechowicz; Qizhen Shi
Journal:  Blood Adv       Date:  2019-09-24

7.  The effect of a supersaturated calcium phosphate mouth rinse on the development of oral mucositis in head and neck cancer patients treated with (chemo)radiation: a single-center, randomized, prospective study of a calcium phosphate mouth rinse + standard of care versus standard of care.

Authors:  Maarten Lambrecht; Carole Mercier; Yasmyne Geussens; Sandra Nuyts
Journal:  Support Care Cancer       Date:  2013-05-18       Impact factor: 3.603

8.  Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis.

Authors:  C Orvain; M P Moles-Moreau; S François; M Mercier; F Moal; J F Hamel; E Parot-Schinkel; N Ifrah; M Hunault-Berger; A Tanguy-Schmidt
Journal:  Support Care Cancer       Date:  2014-08-03       Impact factor: 3.603

9.  Effect of low-level laser therapy on inflammatory mediator release during chemotherapy-induced oral mucositis: a randomized preliminary study.

Authors:  Geisa Badauy Lauria Silva; Nancy Tomoko Sacono; Angélica Ferreira Othon-Leite; Elismauro Francisco Mendonça; Adriano Moraes Arantes; César Bariani; Luciana Garcia Lobo Duarte; Mauro Henrique Nogueira Abreu; Celso Martins Queiroz-Júnior; Tarcília Aparecida Silva; Aline Carvalho Batista
Journal:  Lasers Med Sci       Date:  2014-07-19       Impact factor: 3.161

10.  Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study.

Authors:  Jeevendra Kanagalingam; Mohamed Ibrahim A Wahid; Jin-Ching Lin; Nonette A Cupino; Edward Liu; Jin-Hyoung Kang; Shouki Bazarbashi; Nicole Bender Moreira; Harsha Arumugam; Stefan Mueller; Hanlim Moon
Journal:  Support Care Cancer       Date:  2018-01-31       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.